Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–81
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject was randomized into protocol 20120262 (NCT01970475) and completed the week 26 visit
You may not be if
Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the 20120262 study that could cause extension treatment to be detrimental
Subject completed study 20120262 but cannot be dosed within 4 weeks of the week 26 visit of study 20120262
Current infection requiring the use of oral or intravenous antibiotics
Clareo Health | Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
